SCHEMBL7123375

SCHEMBL7123375

CC(=O)Nc1ccc(Oc2ccc(C(=O)N[C@@H]3C[C@H]4CC[C@@H]3N4)cc2)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
CDK8 P49336 2/20 0.39
MET P08581 1/20 0.38
MMP2 P08253 1/20 0.38
MMP7 P09237 1/20 0.38
MMP9 P14780 1/20 0.38
MMP13 P45452 1/20 0.38
DEGS1 O15121 2/20 0.37
EZH2 Q15910 1/20 0.37
CCNC P24863 1/20 0.36
CDK19 Q9BWU1 1/20 0.36
P2RX3 P56373 1/20 0.36
BTK Q06187 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7123911 0.87 MAPK14 (0.43) P2RX3
SCHEMBL7125176 0.86 HRH3 (0.42) RAB9AMMP2MMP7MMP9MMP13
SCHEMBL7117995 0.86 MMP2 (0.40) MMP2MMP7MMP9MMP13EZH2
SCHEMBL7124977 0.86 MMP2 (0.41) MEN1KMT2AMMP2MMP7MMP9
SCHEMBL7121872 0.85 KCNQ3 (0.46) MEN1KMT2ANPC1RAB9AMMP2
SCHEMBL7125259 0.84 NSD2 (0.41) MEN1KMT2AEZH2PTK2ABL1
SCHEMBL7116059 0.84 POLB (0.39) MEN1KMT2ACASP3SENP8SENP7
SCHEMBL7116944 0.83 HPGD (0.46) RAB9AMMP2MMP7MMP9MMP13
SCHEMBL7124006 0.83 MAPT (0.40) NPC1RAB9AMMP2MMP7MMP9
SCHEMBL7126711 0.83 HRH3 (0.47) KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US claimed
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease CYP7B1, UGT2B7, CYP1B1 MEN1 2572/4885KMT2A 1264/4885NPC1 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.